New attack on deadly eye cancer uses liver treatment to boost immune therapy
NCT ID NCT07276386
Summary
This study is testing a two-step treatment for people with a rare and aggressive eye cancer (uveal melanoma) that has spread mainly to the liver. First, doctors use a procedure to deliver high-dose chemotherapy directly to the liver. The goal is to damage the tumors and potentially make them more visible to the immune system. Then, patients receive an immunotherapy drug (tebentafusp) designed to help the body's immune cells find and attack the remaining cancer cells.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC UVEAL MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.